MAWAG
STOK icon

Mid-American Wealth Advisory Group’s Stoke Therapeutics STOK Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17
Closed -$193 – 286
2025
Q2 		$193 Buy
+17
New +$161 ﹤0.01% 324

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Mid-American Wealth Advisory Group's STOK Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Stoke Therapeutics (STOK) in Q3 2025, closing a stake of 17 shares — an estimated $193 sold.

Mid-American Wealth Advisory Group first reported a position in STOK in Q2 2025 and held it in 1 quarter. The position peaked at $193 in Q2 2025. 151 funds tracked by Wall St. Rank hold STOK as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Stoke Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 17 Stoke Therapeutics shares in Q3 2025, an estimated $193.
  • Mid-American Wealth Advisory Group first reported a position in Stoke Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Stoke Therapeutics position peaked at $193 in Q2 2025.
  • 151 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.